Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanobiotix ( (NBTX) ) just unveiled an update.
On August 27, 2025, Nanobiotix announced its voting rights and share capital details, revealing 48,236,671 shares outstanding as of July 31, 2025. The announcement provides transparency to stakeholders and aligns with regulatory requirements, potentially impacting investor confidence and market positioning.
The most recent analyst rating on (NBTX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, specializing in innovative, physics-based therapeutic approaches. The company is focused on oncology, bioavailability and biodistribution, and disorders of the central nervous system, with over 25 patent families. It is listed on Euronext Paris and the Nasdaq Global Select Market.
Average Trading Volume: 10,415
Technical Sentiment Signal: Buy
Current Market Cap: $410.4M
See more data about NBTX stock on TipRanks’ Stock Analysis page.